21-day R-CHOP regimen remains standard in diffuse B-cell lymphomas Healio A 14-day regimen of rituximab plus CHOP failed to demonstrate improvement compared with the standard 21-day regimen in a cohort of patients with previously B-cell lymphomas, according to results of a multicenter study. Prior studies showed dose ... |
